Literature DB >> 32511434

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease.

Angkana T Huang1,2, Bernardo Garcia-Carreras1,2, Matt D T Hitchings1,2, Bingyi Yang1,2, Leah C Katzelnick1,2, Susan M Rattigan1,2, Brooke A Borgert1,2, Carlos A Moreno1,2, Benjamin D Solomon3, Isabel Rodriguez-Barraquer4, Justin Lessler5, Henrik Salje6, Donald Burke7, Amy Wesolowski5, Derek A T Cummings1,2.   

Abstract

The duration and nature of immunity generated in response to SARS-CoV-2 infection is unknown. Many public health responses and modeled scenarios for COVID-19 outbreaks caused by SARSCoV-2 assume that infection results in an immune response that protects individuals from future infections or illness for some amount of time. The timescale of protection is a critical determinant of the future impact of the pathogen. The presence or absence of protective immunity due to infection or vaccination (when available) will affect future transmission and illness severity. The dynamics of immunity and nature of protection are relevant to discussions surrounding therapeutic use of convalescent sera as well as efforts to identify individuals with protective immunity. Here, we review the scientific literature on antibody immunity to coronaviruses, including SARS-CoV-2 as well as the related SARS-CoV-1, MERS-CoV and human endemic coronaviruses (HCoVs). We reviewed 1281 abstracts and identified 322 manuscripts relevant to 5 areas of focus: 1) antibody kinetics, 2) correlates of protection, 3) immunopathogenesis, 4) antigenic diversity and cross-reactivity, and 5) population seroprevalence. While studies of SARS-CoV-2 are necessary to determine immune responses to it, evidence from other coronaviruses can provide clues and guide future research.

Entities:  

Year:  2020        PMID: 32511434      PMCID: PMC7217088          DOI: 10.1101/2020.04.14.20065771

Source DB:  PubMed          Journal:  medRxiv


  123 in total

1.  Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS.

Authors:  M S Yip; H L Leung; P H Li; C Y Cheung; I Dutry; D Li; M Daëron; R Bruzzone; J Sm Peiris; M Jaume
Journal:  Hong Kong Med J       Date:  2016-06       Impact factor: 2.227

2.  Evaluation of inapparent nosocomial severe acute respiratory syndrome coronavirus infection in Vietnam by use of highly specific recombinant truncated nucleocapsid protein-based enzyme-linked immunosorbent assay.

Authors:  Fuxun Yu; Mai Quynh Le; Shingo Inoue; Hong Thi Cam Thai; Futoshi Hasebe; Maria Del Carmen Parquet; Kouichi Morita
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

3.  Children's vaccines do not induce cross reactivity against SARS-CoV.

Authors:  Yang Yu; Huali Jin; Ze Chen; Qingling L Yu; Yijie J Ma; Xiaolin L Sun; Bin Wang
Journal:  J Clin Pathol       Date:  2007-02       Impact factor: 3.411

4.  An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus.

Authors:  David M Patrick; Martin Petric; Danuta M Skowronski; Roland Guasparini; Timothy F Booth; Mel Krajden; Patrick McGeer; Nathalie Bastien; Larry Gustafson; Janet Dubord; Diane Macdonald; Samara T David; Leila F Srour; Robert Parker; Anton Andonov; Judith Isaac-Renton; Nadine Loewen; Gail McNabb; Alan McNabb; Swee-Han Goh; Scott Henwick; Caroline Astell; Jian Ping Guo; Michael Drebot; Raymond Tellier; Francis Plummer; Robert C Brunham
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-11       Impact factor: 2.471

5.  Human LINE1 endonuclease domain as a putative target of SARS-associated autoantibodies involved in the pathogenesis of severe acute respiratory syndrome.

Authors:  Wei-ping He; Cui-li Shu; Bo-an Li; Jun Zhao; Yun Cheng
Journal:  Chin Med J (Engl)       Date:  2008-04-05       Impact factor: 2.628

6.  Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome.

Authors:  Wei Liu; Arnaud Fontanet; Pan-He Zhang; Lin Zhan; Zhong-Tao Xin; Laurence Baril; Fang Tang; Hui Lv; Wu-Chun Cao
Journal:  J Infect Dis       Date:  2006-02-09       Impact factor: 5.226

7.  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.

Authors:  Xiaolong Tian; Cheng Li; Ailing Huang; Shuai Xia; Sicong Lu; Zhengli Shi; Lu Lu; Shibo Jiang; Zhenlin Yang; Yanling Wu; Tianlei Ying
Journal:  Emerg Microbes Infect       Date:  2020-02-17       Impact factor: 7.163

8.  Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.

Authors:  Juanjuan Zhao; Quan Yuan; Haiyan Wang; Wei Liu; Xuejiao Liao; Yingying Su; Xin Wang; Jing Yuan; Tingdong Li; Jinxiu Li; Shen Qian; Congming Hong; Fuxiang Wang; Yingxia Liu; Zhaoqin Wang; Qing He; Zhiyong Li; Bin He; Tianying Zhang; Yang Fu; Shengxiang Ge; Lei Liu; Jun Zhang; Ningshao Xia; Zheng Zhang
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

9.  Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen.

Authors:  Nikolaos Spanakis; Sotirios Tsiodras; Bart L Haagmans; V Stalin Raj; Kostantinos Pontikis; Antonia Koutsoukou; Nikolaos G Koulouris; Albert D M E Osterhaus; Marion P G Koopmans; Athanassios Tsakris
Journal:  Int J Antimicrob Agents       Date:  2014-09-18       Impact factor: 5.283

10.  Antigenic relationships amongst coronaviruses.

Authors:  A F Bradburne
Journal:  Arch Gesamte Virusforsch       Date:  1970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.